Energy News / Shareholders Foundation, Inc.

Conatus Pharmaceuticals Inc (NASDAQ:CNAT) Stockholder Investigation over Possible Violations of Securities Laws

Via: ReleaseWire

Updated 8:45 AM CDT, Tue, March 10,2015

An investigation for investors in Conatus Pharmaceuticals Inc (NASDAQ:CNAT) shares over potential securities laws violations by Conatus Pharmaceuticals was announced and NASDAQ:CNAT stockholders should contact the Shareholders Foundation.

San Diego, CA -- (ReleaseWire) -- 03/10/2015 -- An investigation on behalf of investors of Conatus Pharmaceuticals Inc (NASDAQ:CNAT) shares over potential securities laws violations by Conatus Pharmaceuticals and certain of its directors and officers in connection certain financial statements was announced.

Investors who purchased shares of Conatus Pharmaceuticals Inc (NASDAQ:CNAT) have certain options and should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554.

The investigation by a law firm focuses on possible claims on behalf of purchasers of the securities of Conatus Pharmaceuticals Inc (NASDAQ:CNAT) concerning whether a series of statements by Conatus Pharmaceuticals regarding its business, its prospects and its operations were materially false and misleading at the time they were made.

On March 5, 2015, Conatus Pharmaceuticals Inc disclosed that on March 2, 2015, Gary C. Burgess, M.B., Ch.B. M.Med., tendered his resignation as Senior Vice President, Clinical Research and Chief Medical Officer of Conatus Pharmaceuticals Inc., effective April 2, 2015. Shares of Conatus Pharmaceuticals Inc (NASDAQ:CNAT) declined to as low as $5.61 per share on March 6, 2015.

Those who purchased shares of Conatus Pharmaceuticals Inc (NASDAQ:CNAT) have certain options and should contact the Shareholders Foundation.

Contact:
Shareholders Foundation, Inc.
Michael Daniels
3111 Camino Del Rio North - Suite 423
92108 San Diego
Phone: +1-(858)-779-1554
Fax: +1-(858)-605-5739
mail@shareholdersfoundation.com

For more information on this press release visit:
http://www.releasewire.com/press-releases/conatus-pharmaceuticals-inc-nasdaqcnat-stockholder-investigation-over-possible-violations-of-securities-laws-585330.htm

Media Relations Contact
Michael Daniels
858-779-1554
Email: Click to Email Michael Daniels
Web: http://www.ShareholdersFoundation.com